Evidence map›Paper›PMID 27941882›Full record

ArticleOncogene2017

Use of an anti-viral drug, Ribavirin, as an anti-glioblastoma therapeutic.

F Volpin, J Casaos, J Sesen, A Mangraviti, J Choi, N Gorelick, J Frikeche, T Lott, R Felder, S J Scotland and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Oncogene, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers.

0numbers the graph read from it
0cells of the map it votes in
30citing papers in PubMed
3.5field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

30 citing papers in PubMed, 59 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Review
  5. Article
  6. Review
  7. Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Drug repurposing against COVID-19: focus on anticancer agents.Journal of experimental & clinical cancer research : CR · 2020
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

F VolpinDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
J CasaosDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
J SesenDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
A MangravitiDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
J ChoiDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
N GorelickDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
J FrikecheDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
T LottDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
R FelderDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
S J ScotlandDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
T S K Eisinger-MathasonDepartment of Pathology, Abramson Family Cancer Research Institute, University of Pennsylvania, Philadelphia, PA, USA.
H BremDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
B TylerDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
N SkuliDepartment of Neurosurgery, Hunterian Neurosurgical Research Laboratory, Johns Hopkins School of Medicine, Johns Hopkins University, Baltimore, MD, USA.
Johns Hopkins Medicine · USJohns Hopkins University · USCentre de Recherche en Cancérologie de Toulouse · FRUPMC Hillman Cancer Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The median survival for glioblastoma patients is ~15 months despite aggressive surgery and radio-chemotherapy approaches. Thus, developing new therapeutics is necessary to improve the treatment of these invasive brain tumors, which are known to show high levels of the eukaryotic initiation factor, eIF4E, a potent oncogene. Ribavirin, the only clinically approved drug known to target eIF4E, is an anti-viral molecule currently used in hepatitis C treatment. Here, we report the effect of ribavirin on proliferation, cell cycle, cell death and migration of several human and murine glioma cell lines, as well as human glioblastoma stem-like cells, in vitro. In addition, we tested ribavirin efficacy in vivo, alone and in combination with temozolomide and radiation. Our work showed that ribavirin inhibits glioma cell growth and migration, and increases cell cycle arrest and cell death, potentially through modulation of the eIF4E, EZH2 and ERK pathways. We also demonstrate that ribavirin treatment in combination with temozolomide or irradiation increases cell death in glioma cells. Finally and most importantly, ribavirin treatment in vivo significantly enhances chemo-radiotherapy efficacy and improves survival of rats and mice orthotopically implanted with gliosarcoma tumors or glioma stem-like cells, respectively. On the basis of these results, we propose that ribavirin represents a new therapeutic option for glioblastoma patients as an enhancer of the cytotoxic effects of temozolomide and radiotherapy.

Indexed as

Drug RepositioningAnimalsAntineoplastic Combined Chemotherapy ProtocolsAntiviral AgentsBrain NeoplasmsCell Line, TumorCell ProliferationDacarbazineFemaleGlioblastomaHumansMiceMice, NudeRatsRats, Inbred F344RibavirinAntiviral AgentsDacarbazineRibavirinTemozolomide

Identifiers

PMID27941882
OpenAlexW2562383504

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.